Published in:
Open Access
01-12-2010 | Poster presentation
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
Authors:
M Nelson, G Amaya, N Clumeck, C Arns Da Cunha, D Jayaweera, P Junod, L Taisheng, P Tebas, M Stevens, A Buelens, S Vanveggel, K Boven
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
TMC278 had a high virologic response rate, non-inferior to EFV, in two Phase III double-blind trials ECHO (TMC278-C209, NCT00540449) and THRIVE (TMC278-C215, NCT00543725) in treatment-naïve HIV-infected adult patients. As the use of NNRTIs, particularly nevirapine, has been associated with hepatic-related adverse events (AEs), especially in HIV/hepatitis B (HBV) and/or hepatitis C (HCV) co-infected patients, a subgroup analysis of these events was performed on the pooled Week 48 Phase III data. …